Tagged with Cerecin

Aducanumab Approval: Opening the Floodgates for a New Era of Alzheimer’s Treatment?

USA Aducanumab Approval: Opening the Floodgates for a New Era of Alzheimer’s Treatment?

USA With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease (AD) drug since 2003 – PharmaBoardroom has raided its archives to bring key industry stakeholders’ takes on the significance of this decision and what it might mean for…

Singapore: A Myriad of Biotech Financing Strategies

Singapore Singapore: A Myriad of Biotech Financing Strategies

Singapore Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative life sciences start-ups and spin-offs has dramatically increased. These companies have greater access to funds, both from state actors as well as via private equity and public listings, but barriers…

Charles Stacey – President & CEO, Cerecin

Singapore Charles Stacey – President & CEO, Cerecin

Singapore Cerecin’s Charles Stacey outlines the company’s progress in expanding its lead asset into migraine and infantile spasms, how its funding strategy has evolved, why Singapore is still a logical base, and how broader developments in the CNS landscape stand to benefit all stakeholders. Moving to Singapore was a good…

Is CNS the Next Oncology?

Opinion Is CNS the Next Oncology?

Opinion Cerecin’s Charles Stacey looks at the large unmet medical need in diseases of the central nervous system (CNS), the looming socioeconomic burden that these diseases represent, and the innovative solutions needed to counter it. 45 percent of the patient population in neurology remains unserved – they either have no…

Charles Stacey – President & CEO, Cerecin (November 2018)

Singapore Charles Stacey – President & CEO, Cerecin (November 2018)

Singapore Dr Charles Stacey, president and CEO of Brain Health company Cerecin, formerly Accera, discusses the rebrand, new investment, the company’s relocation to Asia, and the upcoming rollout of a global Phase III clinical trial for its innovative new Alzheimer’s drug. As a small, innovative biotech company, we are looking…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page